Search Results

Athletico Physical Therapy has opened a new location in Vermillion on Monday, April 29th at 440 E.

ASPiRA LABS, a Vermillion company today announced it has entered into an agreement with BlueCross BlueShield of Illinois.

Vermillion announced today that it has been granted two new US patents that significantly expand coverage for its core technologies, OVA1 and Overa.

Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced the publication of two independent studies demonstrating that OVA1® (Blood Multivariate Index Assay (MIA) for Ovarian Cancer Risk Assessment) improves ovarian cancer risk detection in women compared to alternative technology, such as CA125 and CA125 & HE4 (Risk of Malignancy Algorithm ROMA)

Vermillion announced today that Valerie Palmieri, President and CEO, will provide a corporate overview at the Canaccord Genuity 2017 Medical Technologies & Diagnostics Forum, being held at the Westin Grand Central Hotel in New York City on November 9, 2017.

Vermillion announced today that it will report its third quarter 2017 financial results on Wednesday, November 8, 2017, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.

A “fireside chat” with Dr. Greg Downey, MD, Executive Vice President, Academic Affairs, National Jewish Health, and Dr. Meghan Vermillion, DVM, PhD, DACLAM, Dir. Comparative Med, Lovelace Biomedical. Moderated by Dr. Jake McDonald, Chief Scientific Officer, Lovelace Biomedical.

Study evaluates the differences in sensitivity of ovarian cancer risk detection between OVA1® Plus and CA125

Conference call is scheduled for 4:30 p.m. ET today.

The paper details the base case of a budget impact model that dynamically tracks the effect of OVA1 adoption in lieu of CA125 in the appropriate patient population on overall cost, both at a plan and per member per month (PMPM) level.